Global Lysosomal Storage Diseases Market

Lysosomal Storage Diseases Comprehensive Study by Application (Hospitals, Ambulatory Surgical Centers), Treatment (Enzyme Replacement Therapy, Stem Cell Therapy, Substrate Reduction Therapy), Indication (Gaucher disease, Cystinosis, Pompe Disease, Fabry Disease, Other) Players and Region - Global Market Outlook to 2030

Lysosomal Storage Diseases Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Lysosomal Storage Diseases
Lysosomal storage disorders are a set of hereditary metabolic diseases that are caused by enzyme deficits in different bodily cells. As a result of enzyme shortages, lysosomal storage disorders are inherited metabolic illnesses defined by an abnormal build-up of numerous harmful chemicals in the body's cells. There are approximately 50 of these ailments in all, and they can affect the skeleton, brain, skin, heart, and central nervous system, among other bodily components. New lysosomal storage diseases are always being discovered. While several of these disorders are undergoing clinical trials, there is presently no approved medication for many lysosomal storage diseases.The key factor driving the growth of the worldwide lysosomal storage disorders therapeutics market is an increase in diagnosis rates due to increased awareness and financial incentives for orphan drug development to recover R&D costs. Other reasons driving global demand for lysosomal storage disorders therapies include increased attention of pharmaceutical companies on research and development of medications for the treatment of uncommon diseases, as well as speedier uptake and market access.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The market for lysosomal storage disorder treatment is very competitive, with only a few large competitors. Few big firms currently dominate the market in terms of market share. The major players are doing extensive research to develop new medication and a proper treatment for the disease. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Lysosomal Storage Diseases market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Shire PLC (United States), Pfizer, Inc (United States), Sanofi (France), BioMarin Pharmaceutical Inc. (United States), Actelion Ltd. (Switzerland), Raptor Pharmaceutical Corp.(United States), Protalix Biotherapeutics Inc. (Israel), Amicus Therapeutics, Inc.(United States), Orphazyme A/S (Denmark) and GC Pharma (South Korea) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Cyclo Therapeutics (United States) and CANbridge Life Sciences Ltd. (China).

Segmentation Overview
AMA Research has segmented the market of Global Lysosomal Storage Diseases market by , Application (Hospitals and Ambulatory Surgical Centers) and Region.



On the basis of geography, the market of Lysosomal Storage Diseases has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment, the sub-segment i.e. Enzyme Replacement Therapy will boost the Lysosomal Storage Diseases market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Indication, the sub-segment i.e. Gaucher disease will boost the Lysosomal Storage Diseases market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Enzyme Replacement Therapy

Market Growth Drivers:
Increasing Incidences of Lysosomal Diseases and Growing Awareness and Increasing Diagnosis Rate

Challenges:
Lack of Treatment Options and Stringent Regulatory Factors

Restraints:
High Cost of Treatment and Underdiagnoses of Lysosomal Storage Diseases

Opportunities:
Increased Investment for Drug Development and Increasing Focus of Pharmaceutical Companies in The Research and Development of Drugs for the Treatment of Rare Diseases

Market Leaders and their expansionary development strategies
In April 2023, Centogene a provider of data-driven answers in rare and neurodegenerative diseases, has extended its partnership with Takeda to diagnose patients with lysosomal storage disorders. Under the renewed one-year partnership agreement, Centogene says it will continue to provide Takeda with access to diagnostic testing for patients around the world.
In February 2020, Takeda to Present Research Advances in Rare Lysosomal Storage. Takeda is also supporting, through an educational grant, a satellite symposium on building a better roadmap for the care of Gaucher patients and sponsoring a satellite symposium on peripheral, central and autonomic neurodegenerative consequences in Lysosomal Disease


Key Target Audience
Drug Companies, Pharmaceutical companies, Research Companies, Medical Research Companies and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Hospitals
  • Ambulatory Surgical Centers
By Treatment
  • Enzyme Replacement Therapy
  • Stem Cell Therapy
  • Substrate Reduction Therapy

By Indication
  • Gaucher disease
  • Cystinosis
  • Pompe Disease
  • Fabry Disease
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Incidences of Lysosomal Diseases and Growing Awareness
      • 3.2.2. Increasing Diagnosis Rate
    • 3.3. Market Challenges
      • 3.3.1. Lack of Treatment Options
      • 3.3.2. Stringent Regulatory Factors
    • 3.4. Market Trends
      • 3.4.1. Enzyme Replacement Therapy
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Lysosomal Storage Diseases, by Application, Treatment, Indication and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Lysosomal Storage Diseases (Value)
      • 5.2.1. Global Lysosomal Storage Diseases by: Application (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Ambulatory Surgical Centers
      • 5.2.2. Global Lysosomal Storage Diseases by: Treatment (Value)
        • 5.2.2.1. Enzyme Replacement Therapy
        • 5.2.2.2. Stem Cell Therapy
        • 5.2.2.3. Substrate Reduction Therapy
      • 5.2.3. Global Lysosomal Storage Diseases by: Indication (Value)
        • 5.2.3.1. Gaucher disease
        • 5.2.3.2. Cystinosis
        • 5.2.3.3. Pompe Disease
        • 5.2.3.4. Fabry Disease
        • 5.2.3.5. Other
      • 5.2.4. Global Lysosomal Storage Diseases Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Lysosomal Storage Diseases: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Shire PLC (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer, Inc (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sanofi (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. BioMarin Pharmaceutical Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Actelion Ltd. (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Raptor Pharmaceutical Corp.(United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Protalix Biotherapeutics Inc. (Israel)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Amicus Therapeutics, Inc.(United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Orphazyme A/S (Denmark)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. GC Pharma (South Korea)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Lysosomal Storage Diseases Sale, by Application, Treatment, Indication and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Lysosomal Storage Diseases (Value)
      • 7.2.1. Global Lysosomal Storage Diseases by: Application (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Ambulatory Surgical Centers
      • 7.2.2. Global Lysosomal Storage Diseases by: Treatment (Value)
        • 7.2.2.1. Enzyme Replacement Therapy
        • 7.2.2.2. Stem Cell Therapy
        • 7.2.2.3. Substrate Reduction Therapy
      • 7.2.3. Global Lysosomal Storage Diseases by: Indication (Value)
        • 7.2.3.1. Gaucher disease
        • 7.2.3.2. Cystinosis
        • 7.2.3.3. Pompe Disease
        • 7.2.3.4. Fabry Disease
        • 7.2.3.5. Other
      • 7.2.4. Global Lysosomal Storage Diseases Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Lysosomal Storage Diseases: by Application(USD Million)
  • Table 2. Lysosomal Storage Diseases Hospitals , by Region USD Million (2018-2023)
  • Table 3. Lysosomal Storage Diseases Ambulatory Surgical Centers , by Region USD Million (2018-2023)
  • Table 4. Lysosomal Storage Diseases: by Treatment(USD Million)
  • Table 5. Lysosomal Storage Diseases Enzyme Replacement Therapy , by Region USD Million (2018-2023)
  • Table 6. Lysosomal Storage Diseases Stem Cell Therapy , by Region USD Million (2018-2023)
  • Table 7. Lysosomal Storage Diseases Substrate Reduction Therapy , by Region USD Million (2018-2023)
  • Table 8. Lysosomal Storage Diseases: by Indication(USD Million)
  • Table 9. Lysosomal Storage Diseases Gaucher disease , by Region USD Million (2018-2023)
  • Table 10. Lysosomal Storage Diseases Cystinosis , by Region USD Million (2018-2023)
  • Table 11. Lysosomal Storage Diseases Pompe Disease , by Region USD Million (2018-2023)
  • Table 12. Lysosomal Storage Diseases Fabry Disease , by Region USD Million (2018-2023)
  • Table 13. Lysosomal Storage Diseases Other , by Region USD Million (2018-2023)
  • Table 14. South America Lysosomal Storage Diseases, by Country USD Million (2018-2023)
  • Table 15. South America Lysosomal Storage Diseases, by Application USD Million (2018-2023)
  • Table 16. South America Lysosomal Storage Diseases, by Treatment USD Million (2018-2023)
  • Table 17. South America Lysosomal Storage Diseases, by Indication USD Million (2018-2023)
  • Table 18. Brazil Lysosomal Storage Diseases, by Application USD Million (2018-2023)
  • Table 19. Brazil Lysosomal Storage Diseases, by Treatment USD Million (2018-2023)
  • Table 20. Brazil Lysosomal Storage Diseases, by Indication USD Million (2018-2023)
  • Table 21. Argentina Lysosomal Storage Diseases, by Application USD Million (2018-2023)
  • Table 22. Argentina Lysosomal Storage Diseases, by Treatment USD Million (2018-2023)
  • Table 23. Argentina Lysosomal Storage Diseases, by Indication USD Million (2018-2023)
  • Table 24. Rest of South America Lysosomal Storage Diseases, by Application USD Million (2018-2023)
  • Table 25. Rest of South America Lysosomal Storage Diseases, by Treatment USD Million (2018-2023)
  • Table 26. Rest of South America Lysosomal Storage Diseases, by Indication USD Million (2018-2023)
  • Table 27. Asia Pacific Lysosomal Storage Diseases, by Country USD Million (2018-2023)
  • Table 28. Asia Pacific Lysosomal Storage Diseases, by Application USD Million (2018-2023)
  • Table 29. Asia Pacific Lysosomal Storage Diseases, by Treatment USD Million (2018-2023)
  • Table 30. Asia Pacific Lysosomal Storage Diseases, by Indication USD Million (2018-2023)
  • Table 31. China Lysosomal Storage Diseases, by Application USD Million (2018-2023)
  • Table 32. China Lysosomal Storage Diseases, by Treatment USD Million (2018-2023)
  • Table 33. China Lysosomal Storage Diseases, by Indication USD Million (2018-2023)
  • Table 34. Japan Lysosomal Storage Diseases, by Application USD Million (2018-2023)
  • Table 35. Japan Lysosomal Storage Diseases, by Treatment USD Million (2018-2023)
  • Table 36. Japan Lysosomal Storage Diseases, by Indication USD Million (2018-2023)
  • Table 37. India Lysosomal Storage Diseases, by Application USD Million (2018-2023)
  • Table 38. India Lysosomal Storage Diseases, by Treatment USD Million (2018-2023)
  • Table 39. India Lysosomal Storage Diseases, by Indication USD Million (2018-2023)
  • Table 40. South Korea Lysosomal Storage Diseases, by Application USD Million (2018-2023)
  • Table 41. South Korea Lysosomal Storage Diseases, by Treatment USD Million (2018-2023)
  • Table 42. South Korea Lysosomal Storage Diseases, by Indication USD Million (2018-2023)
  • Table 43. Taiwan Lysosomal Storage Diseases, by Application USD Million (2018-2023)
  • Table 44. Taiwan Lysosomal Storage Diseases, by Treatment USD Million (2018-2023)
  • Table 45. Taiwan Lysosomal Storage Diseases, by Indication USD Million (2018-2023)
  • Table 46. Australia Lysosomal Storage Diseases, by Application USD Million (2018-2023)
  • Table 47. Australia Lysosomal Storage Diseases, by Treatment USD Million (2018-2023)
  • Table 48. Australia Lysosomal Storage Diseases, by Indication USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Lysosomal Storage Diseases, by Application USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Lysosomal Storage Diseases, by Treatment USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Lysosomal Storage Diseases, by Indication USD Million (2018-2023)
  • Table 52. Europe Lysosomal Storage Diseases, by Country USD Million (2018-2023)
  • Table 53. Europe Lysosomal Storage Diseases, by Application USD Million (2018-2023)
  • Table 54. Europe Lysosomal Storage Diseases, by Treatment USD Million (2018-2023)
  • Table 55. Europe Lysosomal Storage Diseases, by Indication USD Million (2018-2023)
  • Table 56. Germany Lysosomal Storage Diseases, by Application USD Million (2018-2023)
  • Table 57. Germany Lysosomal Storage Diseases, by Treatment USD Million (2018-2023)
  • Table 58. Germany Lysosomal Storage Diseases, by Indication USD Million (2018-2023)
  • Table 59. France Lysosomal Storage Diseases, by Application USD Million (2018-2023)
  • Table 60. France Lysosomal Storage Diseases, by Treatment USD Million (2018-2023)
  • Table 61. France Lysosomal Storage Diseases, by Indication USD Million (2018-2023)
  • Table 62. Italy Lysosomal Storage Diseases, by Application USD Million (2018-2023)
  • Table 63. Italy Lysosomal Storage Diseases, by Treatment USD Million (2018-2023)
  • Table 64. Italy Lysosomal Storage Diseases, by Indication USD Million (2018-2023)
  • Table 65. United Kingdom Lysosomal Storage Diseases, by Application USD Million (2018-2023)
  • Table 66. United Kingdom Lysosomal Storage Diseases, by Treatment USD Million (2018-2023)
  • Table 67. United Kingdom Lysosomal Storage Diseases, by Indication USD Million (2018-2023)
  • Table 68. Netherlands Lysosomal Storage Diseases, by Application USD Million (2018-2023)
  • Table 69. Netherlands Lysosomal Storage Diseases, by Treatment USD Million (2018-2023)
  • Table 70. Netherlands Lysosomal Storage Diseases, by Indication USD Million (2018-2023)
  • Table 71. Rest of Europe Lysosomal Storage Diseases, by Application USD Million (2018-2023)
  • Table 72. Rest of Europe Lysosomal Storage Diseases, by Treatment USD Million (2018-2023)
  • Table 73. Rest of Europe Lysosomal Storage Diseases, by Indication USD Million (2018-2023)
  • Table 74. MEA Lysosomal Storage Diseases, by Country USD Million (2018-2023)
  • Table 75. MEA Lysosomal Storage Diseases, by Application USD Million (2018-2023)
  • Table 76. MEA Lysosomal Storage Diseases, by Treatment USD Million (2018-2023)
  • Table 77. MEA Lysosomal Storage Diseases, by Indication USD Million (2018-2023)
  • Table 78. Middle East Lysosomal Storage Diseases, by Application USD Million (2018-2023)
  • Table 79. Middle East Lysosomal Storage Diseases, by Treatment USD Million (2018-2023)
  • Table 80. Middle East Lysosomal Storage Diseases, by Indication USD Million (2018-2023)
  • Table 81. Africa Lysosomal Storage Diseases, by Application USD Million (2018-2023)
  • Table 82. Africa Lysosomal Storage Diseases, by Treatment USD Million (2018-2023)
  • Table 83. Africa Lysosomal Storage Diseases, by Indication USD Million (2018-2023)
  • Table 84. North America Lysosomal Storage Diseases, by Country USD Million (2018-2023)
  • Table 85. North America Lysosomal Storage Diseases, by Application USD Million (2018-2023)
  • Table 86. North America Lysosomal Storage Diseases, by Treatment USD Million (2018-2023)
  • Table 87. North America Lysosomal Storage Diseases, by Indication USD Million (2018-2023)
  • Table 88. United States Lysosomal Storage Diseases, by Application USD Million (2018-2023)
  • Table 89. United States Lysosomal Storage Diseases, by Treatment USD Million (2018-2023)
  • Table 90. United States Lysosomal Storage Diseases, by Indication USD Million (2018-2023)
  • Table 91. Canada Lysosomal Storage Diseases, by Application USD Million (2018-2023)
  • Table 92. Canada Lysosomal Storage Diseases, by Treatment USD Million (2018-2023)
  • Table 93. Canada Lysosomal Storage Diseases, by Indication USD Million (2018-2023)
  • Table 94. Mexico Lysosomal Storage Diseases, by Application USD Million (2018-2023)
  • Table 95. Mexico Lysosomal Storage Diseases, by Treatment USD Million (2018-2023)
  • Table 96. Mexico Lysosomal Storage Diseases, by Indication USD Million (2018-2023)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Lysosomal Storage Diseases: by Application(USD Million)
  • Table 108. Lysosomal Storage Diseases Hospitals , by Region USD Million (2025-2030)
  • Table 109. Lysosomal Storage Diseases Ambulatory Surgical Centers , by Region USD Million (2025-2030)
  • Table 110. Lysosomal Storage Diseases: by Treatment(USD Million)
  • Table 111. Lysosomal Storage Diseases Enzyme Replacement Therapy , by Region USD Million (2025-2030)
  • Table 112. Lysosomal Storage Diseases Stem Cell Therapy , by Region USD Million (2025-2030)
  • Table 113. Lysosomal Storage Diseases Substrate Reduction Therapy , by Region USD Million (2025-2030)
  • Table 114. Lysosomal Storage Diseases: by Indication(USD Million)
  • Table 115. Lysosomal Storage Diseases Gaucher disease , by Region USD Million (2025-2030)
  • Table 116. Lysosomal Storage Diseases Cystinosis , by Region USD Million (2025-2030)
  • Table 117. Lysosomal Storage Diseases Pompe Disease , by Region USD Million (2025-2030)
  • Table 118. Lysosomal Storage Diseases Fabry Disease , by Region USD Million (2025-2030)
  • Table 119. Lysosomal Storage Diseases Other , by Region USD Million (2025-2030)
  • Table 120. South America Lysosomal Storage Diseases, by Country USD Million (2025-2030)
  • Table 121. South America Lysosomal Storage Diseases, by Application USD Million (2025-2030)
  • Table 122. South America Lysosomal Storage Diseases, by Treatment USD Million (2025-2030)
  • Table 123. South America Lysosomal Storage Diseases, by Indication USD Million (2025-2030)
  • Table 124. Brazil Lysosomal Storage Diseases, by Application USD Million (2025-2030)
  • Table 125. Brazil Lysosomal Storage Diseases, by Treatment USD Million (2025-2030)
  • Table 126. Brazil Lysosomal Storage Diseases, by Indication USD Million (2025-2030)
  • Table 127. Argentina Lysosomal Storage Diseases, by Application USD Million (2025-2030)
  • Table 128. Argentina Lysosomal Storage Diseases, by Treatment USD Million (2025-2030)
  • Table 129. Argentina Lysosomal Storage Diseases, by Indication USD Million (2025-2030)
  • Table 130. Rest of South America Lysosomal Storage Diseases, by Application USD Million (2025-2030)
  • Table 131. Rest of South America Lysosomal Storage Diseases, by Treatment USD Million (2025-2030)
  • Table 132. Rest of South America Lysosomal Storage Diseases, by Indication USD Million (2025-2030)
  • Table 133. Asia Pacific Lysosomal Storage Diseases, by Country USD Million (2025-2030)
  • Table 134. Asia Pacific Lysosomal Storage Diseases, by Application USD Million (2025-2030)
  • Table 135. Asia Pacific Lysosomal Storage Diseases, by Treatment USD Million (2025-2030)
  • Table 136. Asia Pacific Lysosomal Storage Diseases, by Indication USD Million (2025-2030)
  • Table 137. China Lysosomal Storage Diseases, by Application USD Million (2025-2030)
  • Table 138. China Lysosomal Storage Diseases, by Treatment USD Million (2025-2030)
  • Table 139. China Lysosomal Storage Diseases, by Indication USD Million (2025-2030)
  • Table 140. Japan Lysosomal Storage Diseases, by Application USD Million (2025-2030)
  • Table 141. Japan Lysosomal Storage Diseases, by Treatment USD Million (2025-2030)
  • Table 142. Japan Lysosomal Storage Diseases, by Indication USD Million (2025-2030)
  • Table 143. India Lysosomal Storage Diseases, by Application USD Million (2025-2030)
  • Table 144. India Lysosomal Storage Diseases, by Treatment USD Million (2025-2030)
  • Table 145. India Lysosomal Storage Diseases, by Indication USD Million (2025-2030)
  • Table 146. South Korea Lysosomal Storage Diseases, by Application USD Million (2025-2030)
  • Table 147. South Korea Lysosomal Storage Diseases, by Treatment USD Million (2025-2030)
  • Table 148. South Korea Lysosomal Storage Diseases, by Indication USD Million (2025-2030)
  • Table 149. Taiwan Lysosomal Storage Diseases, by Application USD Million (2025-2030)
  • Table 150. Taiwan Lysosomal Storage Diseases, by Treatment USD Million (2025-2030)
  • Table 151. Taiwan Lysosomal Storage Diseases, by Indication USD Million (2025-2030)
  • Table 152. Australia Lysosomal Storage Diseases, by Application USD Million (2025-2030)
  • Table 153. Australia Lysosomal Storage Diseases, by Treatment USD Million (2025-2030)
  • Table 154. Australia Lysosomal Storage Diseases, by Indication USD Million (2025-2030)
  • Table 155. Rest of Asia-Pacific Lysosomal Storage Diseases, by Application USD Million (2025-2030)
  • Table 156. Rest of Asia-Pacific Lysosomal Storage Diseases, by Treatment USD Million (2025-2030)
  • Table 157. Rest of Asia-Pacific Lysosomal Storage Diseases, by Indication USD Million (2025-2030)
  • Table 158. Europe Lysosomal Storage Diseases, by Country USD Million (2025-2030)
  • Table 159. Europe Lysosomal Storage Diseases, by Application USD Million (2025-2030)
  • Table 160. Europe Lysosomal Storage Diseases, by Treatment USD Million (2025-2030)
  • Table 161. Europe Lysosomal Storage Diseases, by Indication USD Million (2025-2030)
  • Table 162. Germany Lysosomal Storage Diseases, by Application USD Million (2025-2030)
  • Table 163. Germany Lysosomal Storage Diseases, by Treatment USD Million (2025-2030)
  • Table 164. Germany Lysosomal Storage Diseases, by Indication USD Million (2025-2030)
  • Table 165. France Lysosomal Storage Diseases, by Application USD Million (2025-2030)
  • Table 166. France Lysosomal Storage Diseases, by Treatment USD Million (2025-2030)
  • Table 167. France Lysosomal Storage Diseases, by Indication USD Million (2025-2030)
  • Table 168. Italy Lysosomal Storage Diseases, by Application USD Million (2025-2030)
  • Table 169. Italy Lysosomal Storage Diseases, by Treatment USD Million (2025-2030)
  • Table 170. Italy Lysosomal Storage Diseases, by Indication USD Million (2025-2030)
  • Table 171. United Kingdom Lysosomal Storage Diseases, by Application USD Million (2025-2030)
  • Table 172. United Kingdom Lysosomal Storage Diseases, by Treatment USD Million (2025-2030)
  • Table 173. United Kingdom Lysosomal Storage Diseases, by Indication USD Million (2025-2030)
  • Table 174. Netherlands Lysosomal Storage Diseases, by Application USD Million (2025-2030)
  • Table 175. Netherlands Lysosomal Storage Diseases, by Treatment USD Million (2025-2030)
  • Table 176. Netherlands Lysosomal Storage Diseases, by Indication USD Million (2025-2030)
  • Table 177. Rest of Europe Lysosomal Storage Diseases, by Application USD Million (2025-2030)
  • Table 178. Rest of Europe Lysosomal Storage Diseases, by Treatment USD Million (2025-2030)
  • Table 179. Rest of Europe Lysosomal Storage Diseases, by Indication USD Million (2025-2030)
  • Table 180. MEA Lysosomal Storage Diseases, by Country USD Million (2025-2030)
  • Table 181. MEA Lysosomal Storage Diseases, by Application USD Million (2025-2030)
  • Table 182. MEA Lysosomal Storage Diseases, by Treatment USD Million (2025-2030)
  • Table 183. MEA Lysosomal Storage Diseases, by Indication USD Million (2025-2030)
  • Table 184. Middle East Lysosomal Storage Diseases, by Application USD Million (2025-2030)
  • Table 185. Middle East Lysosomal Storage Diseases, by Treatment USD Million (2025-2030)
  • Table 186. Middle East Lysosomal Storage Diseases, by Indication USD Million (2025-2030)
  • Table 187. Africa Lysosomal Storage Diseases, by Application USD Million (2025-2030)
  • Table 188. Africa Lysosomal Storage Diseases, by Treatment USD Million (2025-2030)
  • Table 189. Africa Lysosomal Storage Diseases, by Indication USD Million (2025-2030)
  • Table 190. North America Lysosomal Storage Diseases, by Country USD Million (2025-2030)
  • Table 191. North America Lysosomal Storage Diseases, by Application USD Million (2025-2030)
  • Table 192. North America Lysosomal Storage Diseases, by Treatment USD Million (2025-2030)
  • Table 193. North America Lysosomal Storage Diseases, by Indication USD Million (2025-2030)
  • Table 194. United States Lysosomal Storage Diseases, by Application USD Million (2025-2030)
  • Table 195. United States Lysosomal Storage Diseases, by Treatment USD Million (2025-2030)
  • Table 196. United States Lysosomal Storage Diseases, by Indication USD Million (2025-2030)
  • Table 197. Canada Lysosomal Storage Diseases, by Application USD Million (2025-2030)
  • Table 198. Canada Lysosomal Storage Diseases, by Treatment USD Million (2025-2030)
  • Table 199. Canada Lysosomal Storage Diseases, by Indication USD Million (2025-2030)
  • Table 200. Mexico Lysosomal Storage Diseases, by Application USD Million (2025-2030)
  • Table 201. Mexico Lysosomal Storage Diseases, by Treatment USD Million (2025-2030)
  • Table 202. Mexico Lysosomal Storage Diseases, by Indication USD Million (2025-2030)
  • Table 203. Research Programs/Design for This Report
  • Table 204. Key Data Information from Secondary Sources
  • Table 205. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Lysosomal Storage Diseases: by Application USD Million (2018-2023)
  • Figure 5. Global Lysosomal Storage Diseases: by Treatment USD Million (2018-2023)
  • Figure 6. Global Lysosomal Storage Diseases: by Indication USD Million (2018-2023)
  • Figure 7. South America Lysosomal Storage Diseases Share (%), by Country
  • Figure 8. Asia Pacific Lysosomal Storage Diseases Share (%), by Country
  • Figure 9. Europe Lysosomal Storage Diseases Share (%), by Country
  • Figure 10. MEA Lysosomal Storage Diseases Share (%), by Country
  • Figure 11. North America Lysosomal Storage Diseases Share (%), by Country
  • Figure 12. Global Lysosomal Storage Diseases share by Players 2023 (%)
  • Figure 13. Global Lysosomal Storage Diseases share by Players (Top 3) 2023(%)
  • Figure 14. Global Lysosomal Storage Diseases share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Shire PLC (United States) Revenue, Net Income and Gross profit
  • Figure 17. Shire PLC (United States) Revenue: by Geography 2023
  • Figure 18. Pfizer, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 19. Pfizer, Inc (United States) Revenue: by Geography 2023
  • Figure 20. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 21. Sanofi (France) Revenue: by Geography 2023
  • Figure 22. BioMarin Pharmaceutical Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. BioMarin Pharmaceutical Inc. (United States) Revenue: by Geography 2023
  • Figure 24. Actelion Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. Actelion Ltd. (Switzerland) Revenue: by Geography 2023
  • Figure 26. Raptor Pharmaceutical Corp.(United States) Revenue, Net Income and Gross profit
  • Figure 27. Raptor Pharmaceutical Corp.(United States) Revenue: by Geography 2023
  • Figure 28. Protalix Biotherapeutics Inc. (Israel) Revenue, Net Income and Gross profit
  • Figure 29. Protalix Biotherapeutics Inc. (Israel) Revenue: by Geography 2023
  • Figure 30. Amicus Therapeutics, Inc.(United States) Revenue, Net Income and Gross profit
  • Figure 31. Amicus Therapeutics, Inc.(United States) Revenue: by Geography 2023
  • Figure 32. Orphazyme A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 33. Orphazyme A/S (Denmark) Revenue: by Geography 2023
  • Figure 34. GC Pharma (South Korea) Revenue, Net Income and Gross profit
  • Figure 35. GC Pharma (South Korea) Revenue: by Geography 2023
  • Figure 36. Global Lysosomal Storage Diseases: by Application USD Million (2025-2030)
  • Figure 37. Global Lysosomal Storage Diseases: by Treatment USD Million (2025-2030)
  • Figure 38. Global Lysosomal Storage Diseases: by Indication USD Million (2025-2030)
  • Figure 39. South America Lysosomal Storage Diseases Share (%), by Country
  • Figure 40. Asia Pacific Lysosomal Storage Diseases Share (%), by Country
  • Figure 41. Europe Lysosomal Storage Diseases Share (%), by Country
  • Figure 42. MEA Lysosomal Storage Diseases Share (%), by Country
  • Figure 43. North America Lysosomal Storage Diseases Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Shire PLC (United States)
  • Pfizer, Inc (United States)
  • Sanofi (France)
  • BioMarin Pharmaceutical Inc. (United States)
  • Actelion Ltd. (Switzerland)
  • Raptor Pharmaceutical Corp.(United States)
  • Protalix Biotherapeutics Inc. (Israel)
  • Amicus Therapeutics, Inc.(United States)
  • Orphazyme A/S (Denmark)
  • GC Pharma (South Korea)
Additional players considered in the study are as follows:
Cyclo Therapeutics (United States) , CANbridge Life Sciences Ltd. (China)
Select User Access Type

Key Highlights of Report


Jan 2024 219 Pages 82 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Lysosomal Storage Diseases Market Quantitative research analysis
Global Lysosomal Storage Diseases Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Shire PLC (United States), Pfizer, Inc (United States), Sanofi (France), BioMarin Pharmaceutical Inc. (United States), Actelion Ltd. (Switzerland), Raptor Pharmaceutical Corp.(United States), Protalix Biotherapeutics Inc. (Israel), Amicus Therapeutics, Inc.(United States), Orphazyme A/S (Denmark) and GC Pharma (South Korea) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Enzyme Replacement Therapy" is seen as one of major influencing trends for Lysosomal Storage Diseases Market during projected period 2023-2030.
The Lysosomal Storage Diseases market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Lysosomal Storage Diseases Market Report?

Have a Query? Click Here

Other Related Reports

Male Infertility Comprehensive Study by Treatment (Assisted Reproductive Technology (In-Vitro Fertilization (IVF), Intracytoplasmic Sperm Injection (ICSI)), Varicocele Surgery, Medication), Test (DNA...
$ 3750
Postmenopausal Vaginal Atrophy Treatment Comprehensive Study by Type (Prasterone (Intrarosa)), Application (Vaginal estrogen cream (Estrace, Premarin). You insert this cream directly into your vagina...
$ 3650
Meningitis Diagnostic Testing Comprehensive Study by Application (Viral Meningitis, Bacterial Meningitis, Fungal Meningitis, Hib Meningitis, Others), Test Type (Latex Agglutination Tests, Lateral Flo...
$ 3650
Hemostasis Diagnostics Comprehensive Study by Type (Laboratory Analyzers (Automated Systems, Semi-automated Systems, Manual Systems), Point-of-Care Testing Systems), Application (Hospital/Clinics, In...
$ 3750
Genetic Modification Therapies Comprehensive Study by Type (Gene Therapies, Genetically Modified Cell Therapies, RNA Therapies, Gene Editing), Application (Hospitals, Diagnostics and Testing Laborato...
$ 3450
Brain Tumor Therapeutics Comprehensive Study by Type (MRI, CT Scan, Tissue Sampling, PET-CT Scan, Cerebral Arteriogram, Lumbar Puncture, Molecular Testing, EEG), Treatment Type (Surgery, Radiation Th...
$ 3650